EMA to review Dynax Heplisav marketing authorization application
Heplisav is indicated for immunization against infection caused by all known subtypes of hepatitis B virus in people aged 18 through 70 years of age and in patients
The US Food and Drug Administration (FDA) has approved two Jazz Pharmaceuticals regimens containing Ziihera (zanidatamab-hrii) for the first-line treatment of adults with unresectable, locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastroesophageal adenocarcinoma (GEA).